Treatment of skin, and wound repair, with thymosin beta 4
AssigneeUnited States of America as represented by The Secretary of Health Office of Technology Transfer
InventorsHynda Kleinman, Allan Goldstein, Katherine Malinda, Gabriel Sosne
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treatment of skin utilizing thymosin β4.
Claims29
A cosmetic composition for topical treatment of skin, comprising from 0.1 ng/ml to 1 μ/ml of human thymosin β4;
- and a cosmetically acceptable vehicle.
A cosmetic composition for topical treatment of skin, comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4;
- human transforming growth factor β1 at a concentration from 5 pg to 1 μg/ml, and a cosmetically acceptable vehicle.
A cosmetic composition for topical treatment of skin, comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4;
- human vascular endothelial growth factor at a concentration from 1 pg/ml to 1 μg/ml and a cosmetically acceptable vehicle.
A method for improving the appearance of the skin, the method comprising:
- applying topically a cosmetic composition comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4;
- and a cosmetically acceptable vehicle.
A method for improving the appearance of the skin, the method comprising:
- applying topically a cosmetic composition comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4, human transforming growth factor β1 at a concentration from 5 pg to 1 μg/ml, and a cosmetically acceptable vehicle.
A method for improving the appearance of the skin, the method comprising:
- applying topically a cosmetic composition comprising from 0.1 ng/ml to 1 μg/ml of human thymosin β4, human vascular endothelial growth factor at a concentration from 1 pg/ml to 1 μg/ml, and a cosmetically acceptable vehicle.
A method for preventing or treating damaged skin, the method comprising:
- applying topically a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4;
- and a vehicle.
A method for preventing or treating damaged skin, the method comprising:
- applying topically a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4, human transforming growth factor β1, and vehicle.
A method for preventing or treating damaged skin, the method comprising:
- applying topically a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4, human vascular endothelial growth factor, and a vehicle.
A composition, comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4 and a vehicle.
A method for treating epithelial tissue, the method comprising:
- administering to a subject a composition comprising from 0.01 ng/ml to 1 μg/ml of human thymosin β4 and a vehicle.
Dependencies are inferred from the claim text.